Volume 14, Number 3—March 2008
Research
Multicenter Cross-Sectional Study of Nontuberculous Mycobacterial Infections among Cystic Fibrosis Patients, Israel
Isaac Levy*1, Galia Grisaru-Soen*12, Liat Lerner-Geva†, Eitan Kerem‡, Hana Blau§, Lea Bentur¶, Micha Aviram#, Joseph Rivlin**, Elie Picard††, Anita Lavy‡‡, Yakov Yahav*, and Galia Rahav*
Table 4
Comparison of patients with NTM infection and NTM disease according to 1997 and 2007 ATS criteria*
| Parameter | 1997 criteria |
2007 criteria |
|||||
|---|---|---|---|---|---|---|---|
| NTM disease (n = 12) | NTM infection (n = 30) | p value | NTM disease (n = 20) | NTM infection (n = 22) | p value | ||
| Age, y (mean ± SD) | 19.8 ± 9.1 | 26.0 ± 11.2 | 0.17 | 24.2 ± 11.7 | 24.3 ± 10.4 | 0.97 | |
| Sex, F/M | 7/5 | 11/19 | 0.20 | 9/11 | 9/13 | 0.79 | |
| No. sputum specimens (mean ± SD) | 9.0 ± 5.1 | 4.4 ± 4.0 | 0.01 | 8.0 ± 5.2 | 3.6 ± 3.2 | 0.003 | |
| BMI, kg/m2 (mean ± SD) | 18.9 ± 1.4 | 20.4 ± 4.0 | 0.19 | 19.7 ± 2.6 | 20.2 ± 4.1 | 0.63 | |
| Hemoptysis | 4 | 6 | 0.36 | 6 | 4 | 0.37 | |
| FEV1, L/s (mean ± SD) | 55.0 ± 23.0 | 57.4 ± 18.4 | 0.75 | 50.7 ± 20.3 | 62.1 ± 17.6 | 0.06 | |
| Pancreatic insufficiency | 9 | 26 | 0.36 | 17 | 18 | 0.78 | |
| Sweat chloride (Meq/L) (mean ± SD) | 66.5 ± 53.3 | 75.7 ± 49.6 | 0.61 | 81.9 ± 45.6 | 65.0 ± 53.7 | 0.28 | |
| Hospitalization, d (mean ± SD) | 50.8 ± 52.5 | 26.2 ± 27.7 | 0.05 | 43.9 ± 44.1 | 23.6 ± 28.0 | 0.09 | |
| Administration of antimicrobial drug therapy, d (mean ± SD) | 87.8 ± 110.9 | 34.7 ± 57.1 | 0.14 | 70.1 ± 90.6 | 31.5 ± 62.7 | 0.12 | |
| Azithromycin | 10 | 20 | 0.55 | 15 | 15 | 0.63 | |
| Azithromycin treatment, d (mean ± SD) | 379.5 ± 258.6 | 362.9 ± 322.7 | 0.87 | 360.7 ± 297.5 | 374.0 ± 314.2 | 0.89 | |
| Ibuprofen | 4 | 1 | 0.01 | 4 | 1 | 0.12 | |
| Insulin | 1 | 3 | 0.87 | 2 | 2 | 0.92 | |
| Systemic steroids | 2 | 1 | 0.13 | 2 | 1 | 0.49 | |
| Inhaled steroids | 10 | 16 | 0.07 | 16 | 10 | 0.02 | |
| AFB in sputum | 7 | 4 | 0.01 | 8 | 3 | 0.05 | |
| Pseudomonas aeruginosa | 12 | 28 | 0.36 | 20 | 20 | 0.17 | |
| Staphylococcus aureus | 7 | 11 | 0.2 | 8 | 10 | 0.72 | |
| Aspergillus spp. | 11 | 17 | 0.03 | 16 | 12 | 0.12 | |
| Allergic bronchopulmonary aspergillosis | 3 | 0 | 0.004 | 3 | 0 | 0.06 | |
| Hemophillus influenza | 2 | 1 | 0.14 | 2 | 1 | 0.52 | |
| Klebsiella pneumoniae | 1 | 2 | 0.85 | 2 | 1 | 0.55 | |
| Stenotrophomonas maltophilia | 2 | 0 | 0.02 | 2 | 0 | 0.14 | |
*NTM, nontuberculous mycobacteria; ATS, American Thoracic Society; SD, standard deviation; BMI, body mass index; FEV1, forced expiratory volume in 1 s; AFB, acid-fast bacilli.
1These authors contributed equally to this work.
2Current affiliation: Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.